Abacus Global Management posted a bifurcated Q2 2026 that demands the reader hold two ideas in tension rather than pick a side. Revenue of $73.0M rose 29.9% year-over-year against a $56.2M Q2 2025, with the entire top-line beat - and then some - coming from the Life Solutions segment, which expanded 38.3% to $65.4M on the back of a $12.99M increase in realized gains on sold and matured life settlement policies. Adjusted EBITDA of $39.94M (54.7% margin) cleared the company's prior framework, and management's same-day guidance call issued Q3 adjusted EPS of 26–28 cents and full-year 2026 adjusted EPS of $1.00–$1.05, both bracketing consensus. The load-bearing observation is that the Asset Management segment, the segment investors were supposed to own ABX for, contracted 17.6% to $7.22M as average management fees on Longevity Funds compressed from 1.45% to 1.05% and ETF Fund fees fell from 0.81% to 0.45%, even as the AUM base in higher-fee Longevity Funds grew 18.8% quarter-over-quarter to $2.57B. The single largest risk is legal and professional fees, which spiked $8.46M in Q2 as the company fights an active defamation suit against Coventry First in U.S. District Court, and the question for the equity is whether $7.6M of business acquisition and non-recurring legal costs are a one-quarter line item or a recurring overhead the market has not yet priced. The next data point that tests the thesis is the Q3 print in early November, where the $1.00–$1.05 full-year framework requires a meaningful acceleration in Asset Management fee revenue or another leg up in Life Solutions realized gains. Two things can both be true: the platform is scaling AUM rapidly and the company is spending heavily to defend its reputation in court, and the equity has re-rated from $5.94 a year ago to $8.92 - a 50% move that reflects neither complacency nor conviction.